These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 17286539)

  • 21. Modern therapy of Parkinson's disease.
    Ransmayr G; Künig G; Gerstenbrand F
    J Neural Transm Suppl; 1992; 38():129-40. PubMed ID: 1491245
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of Parkinson's disease. Psychological disorders: striking a balance in order to optimise antiparkinsonian treatment.
    Prescrire Int; 2011 Oct; 20(120):242-5. PubMed ID: 21970092
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of genetic, biological and pharmacological factors on levodopa dose in Parkinson's disease.
    Altmann V; Schumacher-Schuh AF; Rieck M; Callegari-Jacques SM; Rieder CR; Hutz MH
    Pharmacogenomics; 2016 Apr; 17(5):481-8. PubMed ID: 27019953
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reevaluation of levodopa therapy for the treatment of advanced Parkinson's disease.
    Yokochi M
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S25-30. PubMed ID: 19131038
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tremor-predominant Parkinson's disease. Approaches to treatment.
    Marjama-Lyons J; Koller W
    Drugs Aging; 2000 Apr; 16(4):273-8. PubMed ID: 10874522
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of pharmacogenomics in the personalization of Parkinson's disease treatment.
    Redenšek S; Dolžan V
    Pharmacogenomics; 2020 Sep; 21(14):1033-1043. PubMed ID: 32893736
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nicotine and Nicotinic Receptor Drugs: Potential for Parkinson's Disease and Drug-Induced Movement Disorders.
    Quik M; Bordia T; Zhang D; Perez XA
    Int Rev Neurobiol; 2015; 124():247-71. PubMed ID: 26472532
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Costs of Parkinson's disease and antiparkinsonian pharmacotherapy: an Italian cohort study.
    Winter Y; von Campenhausen S; Reese JP; Balzer-Geldsetzer M; Longo K; Spiga G; Boetzel K; Eggert K; Oertel WH; Dodel R; Barone P
    Neurodegener Dis; 2010; 7(6):365-72. PubMed ID: 20523028
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The history of drugs for the treatment of Parkinson's disease.
    Kapp W
    J Neural Transm Suppl; 1992; 38():1-6. PubMed ID: 1491242
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Treatments for Parkinson's Disease -Essential Knowledge for General Physicians - Topics: III. Recommended Usage of New Antiparkinson Drugs].
    Nagai M
    Nihon Naika Gakkai Zasshi; 2015 Aug; 104(8):1558-64. PubMed ID: 30160420
    [No Abstract]   [Full Text] [Related]  

  • 31. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
    Deleu D; Hanssens Y; Northway MG
    Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment options for early Parkinson's disease.
    Stacy M; Brownlee HJ
    Am Fam Physician; 1996 Mar; 53(4):1281-7. PubMed ID: 8629572
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Early treatment of Parkinson's disease with levodopa].
    Odekerken VJ; Post B; Verschuur CV; de Bie RM
    Ned Tijdschr Geneeskd; 2009; 153():A286. PubMed ID: 19785822
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson's disease.
    Moreau C; Meguig S; Corvol JC; Labreuche J; Vasseur F; Duhamel A; Delval A; Bardyn T; Devedjian JC; Rouaix N; Petyt G; Brefel-Courbon C; Ory-Magne F; Guehl D; Eusebio A; Fraix V; Saulnier PJ; Lagha-Boukbiza O; Durif F; Faighel M; Giordana C; Drapier S; Maltête D; Tranchant C; Houeto JL; Debû B; Azulay JP; Tison F; Destée A; Vidailhet M; Rascol O; Dujardin K; Defebvre L; Bordet R; Sablonnière B; Devos D;
    Brain; 2015 May; 138(Pt 5):1271-83. PubMed ID: 25805645
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Diagnosis and therapy of Parkinson's disease].
    Wittstock M; Benecke R
    MMW Fortschr Med; 2005 May; 147 Spec No 2():28-31. PubMed ID: 15968869
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized trial of pallidotomy versus medical therapy for Parkinson's disease.
    Vitek JL; Bakay RA; Freeman A; Evatt M; Green J; McDonald W; Haber M; Barnhart H; Wahlay N; Triche S; Mewes K; Chockkan V; Zhang JY; DeLong MR
    Ann Neurol; 2003 May; 53(5):558-69. PubMed ID: 12730989
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of Parkinson's disease : what's on the horizon?
    Wu SS; Frucht SJ
    CNS Drugs; 2005; 19(9):723-43. PubMed ID: 16142989
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of dopaminergic replacement therapy on motor speech disorders in Parkinson's disease: longitudinal follow-up study on previously untreated patients.
    Rusz J; Tykalová T; Klempíř J; Čmejla R; Růžička E
    J Neural Transm (Vienna); 2016 Apr; 123(4):379-87. PubMed ID: 26843071
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of subthalamic nucleus stimulation and medication on resting and postural tremor in Parkinson's disease.
    Sturman MM; Vaillancourt DE; Metman LV; Bakay RA; Corcos DM
    Brain; 2004 Sep; 127(Pt 9):2131-43. PubMed ID: 15240437
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current concepts in clinical therapeutics: Parkinson's disease.
    Erwin WG; Turco TF
    Clin Pharm; 1986 Sep; 5(9):742-53. PubMed ID: 3530616
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.